Efficacy of nebulized colistin-based therapy without concurrent intravenous colistin for ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii

Carbapenem resistance in Acinetobacter baumannii(CRAB) infection has become increasingly prevalent worldwide and has been associated with high mortality rate (1-3). Patients with ventilator-associated pneumonia (VAP) caused by carbapenem-resistant CRAB, the incidence of which has been rising substantially, may be predisposed to poor outcome because of limited therapeutic options and the likelihood of inappropriate empirical antibiotic therapy (4,5)